Pharmacy benefit manager shares dropped sharply Wednesday as lawmakers introduced bipartisan legislation requiring health insurers and PBMs to divest pharmacy operations within three years. The proposal intensifies scrutiny of the PBM industry's influence over drug pricing.
Bipartisan Bill Targets Vertical Integration in Healthcare
According to Reuters, following the presentation of a bipartisan measure on Wednesday, which would compel health insurers or drug intermediaries to sell off their pharmacy businesses, shares of companies owning pharmacy benefit managers declined.
The majority of pharmacy benefit management (PBM) in the US is controlled by CVS Health’s Caremark, Cigna’s Express Scripts, and UnitedHealth Group’s Optum. All three of these parent firms also own health insurance businesses.
Following the initial reporting of the bill in the Wall Street Journal, all three firms' shares fell by 4.8% to 5.5%.
The bill, which is being co-sponsored by Republican Josh Hawley and Democratic Elizabeth Warren in the United States Senate, would require, within three years, that companies that own health insurers or pharmacy benefit managers sell their shares in pharmacies.
Healthcare Stocks React to Bipartisan Proposal
This bill will be submitted in Congress with the support of Republican Diana Harshbarger and Democratic Jake Auchincloss.
Pharmacy benefit managers (PBMs) mediate pricing negotiations for prescription prescriptions between insurance companies, pharmacies, and pharmaceutical companies. PBMs then pay pharmacies directly for the medications covered by their contracts.
They have already been investigated for the impact they have on the cost of prescription drugs.
"PBMs have manipulated the market to enrich themselves — hiking up drug costs, cheating employers, and driving small pharmacies out of business. My new bipartisan bill will untangle these conflicts of interest by reining in these middlemen," Senator Warren stated.
Other Insurers Feel the Ripple Effect of PBM Legislation
Other insurance companies' stock prices dropped 1% to 3%. This included Centene, Elevance, and Humana, Investing.com shares.
"The latest introduction of potential legislation to restrict PBM operations and broader healthcare vertical integration is unlikely to gain traction, although it is hard to dismiss outright," Michael Cherny, an analyst at Leerink Partners, said.
Insurance company stock has taken a beating following last week's shooting death of UnitedHealth health insurance unit CEO Brian Thompson outside a Manhattan hotel.


Nvidia Confirms Major OpenAI Investment Amid AI Funding Race
SpaceX Reports $8 Billion Profit as IPO Plans and Starlink Growth Fuel Valuation Buzz
Using the Economic Calendar to Reduce Surprise Driven Losses in Forex
Bob Iger Plans Early Exit as Disney Board Prepares CEO Succession Vote
Panama Supreme Court Voids Hong Kong Firm’s Panama Canal Port Contracts Over Constitutional Violations
Federal Judge Signals Possible Dismissal of xAI Lawsuit Against OpenAI
Climate Adaptation at Home: How Irrigreen Makes Conservation Effortless
NVIDIA, Microsoft, and Amazon Eye Massive OpenAI Investment Amid $100B Funding Push
Oil Prices Surge Toward Biggest Monthly Gains in Years Amid Middle East Tensions
Dollar Holds Firm as Markets Weigh Warsh-Led Fed and Yen Weakness Ahead of Japan Election
Indonesian Stocks Plunge as MSCI Downgrade Risk Sparks Investor Exodus
Apple Earnings Beat Expectations as iPhone Sales Surge to Four-Year High
South Korea Exports Surge in January on AI Chip Demand, Marking Fastest Growth in 4.5 Years
India Budget 2026: Modi Government Eyes Reforms Amid Global Uncertainty and Fiscal Pressures
Trump to Announce New Federal Reserve Chair Pick as Powell Replacement Looms
China Home Prices Rise in January as Government Signals Stronger Support for Property Market 



